Incoming! The Pfizer RSV Vaccine
Pfizer's new RSV vaccine may trigger Guillain-Barre syndrome
This is getting out of hand…
If you haven’t heard Pfizer is getting its latest vaccine ready - this time it’s for respiratory syncytial virus or RSV.
The new vaccine has been flagged by the Food and Drug Administration as posing a potential risk for Guillain-Barre syndrome, a rare neurological condition. According to FDA documents two people in their 60s, who participated in Pfizer’s Phase 3 clinical trials were diagnosed with the illness. One person completely resolved after 3 months and the other person continues to show improvement.
There were also slightly more deaths in the vaccinated group, 52 vs 49 in the placebo recipients. According to Pfizer study investigators, none of the deaths were considered related to vaccination - the FDA agrees with the assessment.
Now this vaccine is on the same expedited timeline as the COVID-19 vaccine. Meaning the timeline for development from as many as eight years has been cut down to two years. Pfizer says it agreed to conduct a safety study (to further asses the risks of Guillain-Barre syndrome) “should the vaccine be approved.” This is exactly what happens when we try to fast-track these vaccines. Shouldn’t the vaccine be safety tested before FDA approval?
The Swine Flu Vaccine was pulled in 1976 after showing a 1 in 100,000 risk of Guillain-Barre syndrome.
GlaxoSmithKline, another protein-based RSV candidate, halted three maternal RSV vaccine clinical trials last year. Its decision was based on safety signals it observed during the trials. The adult version is pending the same fast-track approval as Pfizer.
For now, there are no approved RSV vaccines. We’ve tried before and they were initially ‘well tolerated’ but ultimately failed. The first RSV vaccine in the 1960’s ended up causing vaccine-associated enhanced disease. The vaccine, given to infants and toddlers, caused more serious RSV symptoms when they caught the virus - instead of protecting them.
The new Pfizer vaccine is protein-based and not mRNA. It’s a bivalent vaccine that contains proteins to stimulate immune protection against two types of RSV - RSA A and B.
Pfizer wants to focus their RSV vaccine on pregnant women. The idea is to vaccinate pregnant women and immunize their babies in the womb. They call this maternal immunization.
Trial data released in November shows almost 82% efficacy in protecting against severe disease in babies. Like most Pfizer products, immunity quickly decreases. The 82% efficacy only lasts for 90 days. According to Pfizer:
“If approved, RSVpreF (the vaccine’s internal name) would help protect infants at their first breath from the devastating effects of this infectious disease, which though well-known, has been particularly evident throughout this RSV season.”
The Vaccines and Related Biological Products Advisory Committee (VRBPAC) will meet today to discuss the approval of the vaccine. If approved it is expected to be available this summer. Would you get it?
Dr. Panda's Newsletter is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.
If you find the content on this Substack valuable, please consider becoming a paying subscriber. Your support is greatly appreciated and allows me to continue providing this important information.
I would like to think that they are just incompetent, but it's becoming more and more obvious that they are evil.
We conservatives may be going about this the wrong way. We should be encouraging liberals to take the jab. Convince them to remove themselves from the gene pool, and the voter base.
You have to admit, based on recent events, the world would be a much safer, healthier place without them.